Improving Quality ofLife After Cardiogenic Shock: Do More Revascularization!**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Ohman, E. Magnus & Chang, Patricia P.
EI
L
D
E
P
C
T
c
p
T
p
p
i
h
a
c
h
m
w
d
p
p
(
i
d
d
4
3
3
h
s
p
r
d
I
c
l
S
R
S
t
v
A
C
Journal of the American College of Cardiology Vol. 46, No. 2, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Ps
i
e
i
c
l
a
o
a
c
t
q
a
a
s
r
t
s
s
I
c
g
w
c
7
c
8
I
E
o
f
m
t
g
c
o
h
w
s
p
a
w
c
C
O
c
r
h
h
(
v
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.018DITORIAL COMMENT
mproving Quality of
ife After Cardiogenic Shock:
o More Revascularization!*
. Magnus Ohman, MD, FACC,
atricia P. Chang, MD, MHS, FACC
hapel Hill, North Carolina
he outcome of acute myocardial infarction (AMI) has
hanged dramatically during the last two decades. Most
atients can now expect survival rates of more than 90% (1).
he main reason for this enhanced outcome is the active
ursuit of reperfusion in AMI with fibrinolytic therapy and
rimary percutaneous coronary intervention. As we have
mproved survival, many patients who previously would not
ave survived are now alive, some with low ejection fraction
nd symptomatic heart failure (HF). Patients who develop
ardiogenic shock during AMI are now the group with
ighest mortality, accounting for approximately 60% of the
ortality observed (2). The landmark trial by the SHould
See page 266
e emergently revascularize Occluded Coronaries for Car-
iogenic shocK (SHOCK) investigators has strongly sup-
orted more aggressive management for these highest-risk
atients (3). In this study, the use of early revascularization
ERV) was associated with higher survival compared with
mmediate medical stabilization (IMS), especially after 30
ays, because more patients randomly assigned to IMS died
uring follow-up (30-day survival: ERV, 53.3%; IMS,
4.0%; p  0.11; 6-month survival: ERV, 49.7%; IMS,
6.9%; p  0.027; 1-year survival: ERV, 46.7%; IMS,
3.6%; p  0.03) (3,4). The outcomes of the SHOCK trial
ave lead to a class 1A recommendation for an early invasive
trategy in AMI complicated by cardiogenic shock for
atients who are younger than 75 years of age and a class IIa
ecommendation for the elderly (75 years) (5).
However, the use of early revascularization remains un-
erused. Data from the National Registry of Myocardial
nfarction identified that only 60% of patients with AMI
omplicated by cardiogenic shock underwent early revascu-
arization in hospitals with revascularization capability (6).
imilarly, we have documented recently from the Can
apid Risk Stratification of Unstable Angina Patients
uppress ADverse Outcomes with Early Implementation of
he American College of Cardiology/American Heart As-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Division of Cardiology, The University of North Carolina at Chapel Hill,
hapel Hill, North Carolina.ociation Guidelines (CRUSADE) quality improvement
nitiative that only 49% patients with non–ST-segment
levation MI underwent early revascularization; not surpris-
ngly, the in-hospital mortality among the patients with
ardiogenic shock has remained high, at 41% (7).
Why have these impressive outcomes with early revascu-
arization in cardiogenic shock not led to their widespread
doption in practice? Although the answer to this question
bviously is multifactorial, there has been a concern that
mong the sickest patients with AMI, such as those with
ardiogenic shock, early revascularization might rescue pa-
ients that end up alive but with remnant HF and poor
uality of life (QOL). In this issue of the Journal, Sleeper et
l. (8) provide further evidence why the early invasive and
ggressive approach to cardiogenic shock should be the
tandard of care. They have clearly demonstrated that early
evascularization is associated with better survival and that
hose patients who live largely have good QOL with few
ymptoms of HF.
Patients randomly assigned to ERV had better functional
tatus at one year compared with those randomly assigned to
MS. Although the distribution of New York Heart Asso-
iation (NYHA) functional class was similar by treatment
roups, the ERV group had a higher proportion of those
ith modest functional impairment (NYHA functional
lass I or II) at two weeks after hospital discharge (ERV,
5.9%; IMS, 62.5%). At one year, 83% of patients dis-
harged alive were in NYHA functional class I or II (ERV,
5%; IMS, 80%). The proportion of NYHA functional class
II and IV decreased with more one-year survivors in the
RV group without a proportionate increase in the number
f NYHA functional class III or IV patients. Furthermore,
ewer patients in the IMS group remained stable because
ore patients deteriorated or died. When patients assessed
heir QOL, both the ERV and IMS groups had similarly
ood overall health satisfaction. At two weeks after dis-
harge, the ERV group had higher Multidimensional Index
f Life Quality (MILQ) scores with regard to mental
ealth, physical energy and pain, and financial stability, as
ell as a trend toward a higher Andrews’ Ladder of Life
core.
The findings of Sleeper et al. (8) are consistent with
revious reports that have shown that a more invasive
pproach to AMI or acute coronary syndromes is associated
ith higher survival and improved QOL compared with
onservative management (9,10). When the American and
anadian subpopulations in the Global Use of Strategies to
pen Occluded Coronary Arteries (GUSTO) trial were
ompared, the U.S. cohort, who had a substantially higher
ate of cardiac catheterization and revascularization, had a
igher survival (p  0.02) as well as better functional status,
igher QOL, and less cardiac symptoms one year after AMI
p  0.001) (11). Other recent trials comparing invasive
ersus conservative treatment strategies for acute coronary
yndromes (e.g., Randomized Intervention Trial of unstable
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July 19, 2005:274–6 Editorial Commentngina [RITA]-3, Fragmin and fast revascularization dur-
ng instability in coronary artery disease [FRISC-II]) have
imilarly demonstrated a higher health-related QOL
HRQOL) one year after an interventional strategy (9,10).
Although consistent with other studies in AMI on QOL,
he findings of Sleeper et al. represent probably the most
ositive outlook on QOL after cardiogenic shock. The
umber of patients in their study was 41.7% of the total
HOCK cohort. Thus, the study was somewhat underpow-
red. Furthermore, only 50.8% (n 64) of the study sample
ad sufficient data for the QOL assessments using the
ILQ and life satisfaction questionnaires because these
uestionnaires were valid only if answered by patient and
ot by proxy. This selection bias would likely strengthen the
ssociation between ERV and higher QOL because the
ickest individuals who could not provide their QOL
ere more often from the IMS group, who had lower
ental health status and greater death rates after dis-
harge. However, it is reassuring that most patients had
ew to no symptoms of HF after MI. Because increasing
everity of HF has been linked with poorer QOL, it
annot be emphasized enough that most patients ran-
omly assigned to ERV had NYHA functional class I or
I at two weeks (75.9%) and at one year (85.2%), indicating
he value of early revascularization in preventing significant
eduction in left ventricular function with its resultant
ymptoms of HF.
The SHOCK trial was conducted before the widespread
se of device therapy. Cardiac resynchronization therapy
ained an important place in standard HF therapy after the
arly studies demonstrated significant improvement in
OL before data supported any survival benefit (12).
ecause there were more patients with more severe HF in
he IMS group, it is possible that the effect of cardiac
esynchronization therapy would have minimized the dif-
erences in QOL. Furthermore, the use of implantable
ardioverter defibrillator after MI may overall have im-
roved survival after MI, but this therapy has not improved
OL. On the contrary, it has been associated with worse
OL (13) because 24% of patients may suffer from inap-
ropriate shocks, notwithstanding the very clear mortality
enefit (14). Thus, as our therapies improve among patients
ith HF, we can expect improved QOL in conjunction with
mproved survival, an accomplishment that seemed highly
nlikely more than a decade ago for AMI patients with
ardiogenic shock.
Elderly patients frequently are more concerned about
uality rather than quantity of life. Despite the interaction
etween age and therapy on survival that was observed in
he SHOCK trial, it has been generally accepted in selected
lderly patients that early revascularization is associated with
mproved survival. The authors of the present study did not
xamine whether QOL or functional status differs between
lder and younger patients, probably because of the rela-
ively small number of elderly patients in the SHOCK trial
n  56, age 75 years or older) of which 66.1% already diedy six months. It has been argued that older people have less
o gain than younger people from preventive and aggressive
herapies because of their shorter life expectancy. However,
ost people value time in the near future more than in the
istant future. In a study of patients with HF, older patients
age 65 years) had better HRQOL compared with
ounger patients (p  0.005) despite significant functional
imitations with worse NYHA functional class (p  0.001);
owever, over the course of six weeks, older patients were at
isk for worsening QOL with further decline in functional
tatus (mean HRQOL change of 14.4 points vs. 0.3
oints, p  0.001) (15). These results underscore the
mportance of aiming treatments at maintaining functional
tatus in older persons with HF, which may include early
evascularization in AMI with cardiogenic shock.
Because the SHOCK trial is one of few studies in AMI
hat examines both outcomes of survival and QOL, this
mportant work by Sleeper et al. (8) supports continued
ggressiveness of delivering health care to patients with
ardiogenic shock. Therefore, early revascularization should
e mandated for patients with AMI complicated by
ardiogenic shock to improve both survival and QOL.
his can occur without increasing the proportion of
atients with severe life-limiting HF symptoms. Because
urvival from AMI has greatly improved over the course of
ime, future studies will need to focus more on QOL and
F outcomes.
eprint requests and correspondence: Dr. E. Magnus Ohman,
ivision of Cardiology, The University of North Carolina at
hapel Hill, CB#7075, Chapel Hill, North Carolina 27599-7075.
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